Eprosartan Mesylate

HCID 5282474

Notes Reactions

Substructure search Find similar structures

Basic information

CAS: 144143-96-4
Standard SMILES: CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1.CS(=O)(=O)O
InChIKey: DJSLTDBPKHORNY-XMMWENQYSA-N
Molecular formula: C24H28N2O7S2
Average molar mass: 520.6 g/mol
Monoisotopic mass: 520.13379358

Names & identifiers

Preferred name: Eprosartan Mesylate
IUPAC: 4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid;methanesulfonic acid
English name: Eprosartan mesylate
Molecular formula: C24H28N2O7S2
Molecular weight: 520.62

Names & synonyms

EPROSARTAN MESYLATETevetenEprosartan mesilateeprosartan methanesulfonateEprosartan MonomethanesulfonateSK&F 108566-JDTXSID7044217UNII-8N2L1NX8S3SK&F-108566-J8N2L1NX8S3DTXCID5024217CHEBI:48409

Show more names

Eprosartan MyslateEposartan mesylateMonomethanesulfonateEprosartanMesylate>Eprosartan mesylate, >=99%Eprosartan mesylate USP/EP/BPSunitinib and its interMediate

(E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid, monomethanesulfonateTEVETEN HCT COMPONENT EPROSARTAN MESYLATE2-Thiophenepropanoic acid, alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazol-5-yl)methylene)-, (E)-, monomethanesulfonateEPROSARTAN MESILATE (MART.)EPROSARTAN MESILATE [MART.]EPROSARTAN MESYLATE (USP-RS)EPROSARTAN MESYLATE [USP-RS](E)-alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazol-5-yl)methylene)-2-thiophenepropanoic acid monomethanesulfonate

Database identifiers

CAS: 144143-96-4
PubChem CID: 5282474
DTXSID: DTXSID7044217
ChEMBL: CHEMBL1200987
ChEBI: CHEBI:48409
UNII: 8N2L1NX8S3

Properties

Computed structural properties

Topological polar surface area: 183 Å²
Hydrogen bond donors: 3
Hydrogen bond acceptors: 9
Rotatable bonds: 10
Heavy atoms: 35
Formal charge: 0
Complexity: 711

Physicochemical properties

Melting point: 248 · 248-250°
storage temp.: Sealed in dry,Room Temperature
solubility: 10 mg/mL · DMSO: >10mg/mL
form: powder
color: white to off-white
Merck: 14 · 14,3635
Major Application: pharmaceutical (small molecule)
InChIKey: DJSLTDBPKHORNY-XMMWENQYSA-N
SMILES: S(O)(=O)(=O)C.C(C1C=CC(C(=O)O)=CC=1)N1C(=NC=C1/C=C(/C(=O)O)\CC1SC=CC=1)CCCC
CAS DataBase Reference: 144143 · 144143-96-4(CAS DataBase Reference)
FDA UNII: 8 N2L1NX8S3 · 8N2L1NX8S3
UNSPSC Code: 41116107 · 41116107
NACRES: 24 · NA.24
Symbol(GHS): 7 · GHS07
Signal word: Warning
Hazard statements: 315 · H315-H319
Precautionary statements: 305 · P305+P351+P338
Hazard Codes: Xi
Risk Statements: 36 · 36/37/38
Safety Statements: 26 · 26
WGK Germany: 3 · 3
RTECS: 282400 · XN0282400
HS Code: 29349990 · 29349990
Storage Class: 11 · 11 - Combustible Solids
Hazard Classifications: 2 Skin · Eye Irrit. 2Skin Irrit. 2

Safety & regulation

Toxicology

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Eprosartan mesylate

Ambiguous-DILI-concern

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation · 1 item

◉ Summary of Use during Lactation；Eprosartan is no longer marketed in the US. Because no information is available on the use of eprosartan during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.；◉ Effects in Breastfed Infants；Relevant published information was not found as of the revision date.；◉ Effects on Lactation and Breastmilk；Relevant published information was not found as of the revision date.